Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report ...

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...

Pharvaris (PHVS) is climbing 3% after investment bank JMP Securities raised its price target on the shares to $55, based on ...

Fintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Market Outperform recommendation. As of January 28, 2025, the average ...

CAMBRIDGE, Mass. & SALISBURY, England, January 08, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of ...